Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 3697-3705, 2010.
Article
em En
| WPRIM
| ID: wpr-336561
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To highlight recent researches which may show promise for histomolecular classification and new treatments for gliomas.</p><p><b>DATA SOURCES</b>All articles cited in this review were mainly searched from PubMed, which were published in English from 1996 to 2010.</p><p><b>STUDY SELECTION</b>Original articles and critical reviews selected were relevant to the isocitrate dehydrogenase-1/2 mutation in gliomas and other tumors.</p><p><b>RESULTS</b>Extraordinary high rates of somatic mutations in isocitrate dehydrogenase-1/2 occur in the majority of World Health Organization grade II and grade III gliomas as well as grade IV secondary glioblastomas. Isocitrate dehydrogenase-1/2 mutations are associated with younger age at diagnosis and a better prognosis in patients with mutated tumors. The functional role of isocitrate dehydrogenase-1/2 mutations in the pathogenesis of gliomas is still unclear.</p><p><b>CONCLUSION</b>Isocitrate dehydrogenase-1/2 mutations define a specific subtype of gliomas and may have great significance in the diagnosis, prognosis, and treatment of patients with these tumors.</p>
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Patologia
/
Fisiologia
/
Prognóstico
/
Neoplasias Encefálicas
/
Genes p53
/
Fatores Etários
/
Gradação de Tumores
/
Genética
/
Glioma
/
Glutaratos
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Chinese Medical Journal
Ano de publicação:
2010
Tipo de documento:
Article